These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33414441)

  • 41. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
    Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ
    Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
    Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
    Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
    Blanc C; Moktefi A; Jolly A; de la Grange P; Gay D; Nicolaiew N; Semprez F; Maillé P; Soyeux P; Firlej V; Vacherot F; Destouches D; Amiche M; Terry S; de la Taille A; Londoño-Vallejo A; Allory Y; Delbé J; Hamma-Kourbali Y
    Br J Cancer; 2023 Mar; 128(5):918-927. PubMed ID: 36550208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
    Sabnis NG; Miller A; Titus MA; Huss WJ
    Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small Cell/Neuroendocrine Prostate Cancer: A Rare Treatment-Resistant Variant Presenting as Acute Onset Severe Back Pain.
    Khine ST; Ajmal S; Azher Q; Singh A
    Cureus; 2024 Jan; 16(1):e52379. PubMed ID: 38361678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer.
    Nie J; Zhang P; Liang C; Yu Y; Wang X
    Free Radic Biol Med; 2023 Aug; 205():318-331. PubMed ID: 37355053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sympathetic signaling facilitates progression of neuroendocrine prostate cancer.
    Dwivedi S; Bautista M; Shrestha S; Elhasasna H; Chaphekar T; Vizeacoumar FS; Krishnan A
    Cell Death Discov; 2021 Nov; 7(1):364. PubMed ID: 34811362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
    Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
    Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
    Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
    Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
    Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
    Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
    Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer.
    Case TC; Merkel A; Ramirez-Solano M; Liu Q; Sterling JA; Jin R
    Transl Oncol; 2021 Nov; 14(11):101213. PubMed ID: 34461557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate
    Zhou H; He Q; Li C; Alsharafi BLM; Deng L; Long Z; Gan Y
    Front Cell Dev Biol; 2022; 10():955669. PubMed ID: 35938167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNA-1205 Regulation of FRYL in Prostate Cancer.
    Naidoo M; Levine F; Gillot T; Orunmuyi AT; Olapade-Olaopa EO; Ali T; Krampis K; Pan C; Dorsaint P; Sboner A; Ogunwobi OO
    Front Cell Dev Biol; 2021; 9():647485. PubMed ID: 34386489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.